Abstract:Patients suffering from severe aplastic anemia (SAA) need frequent blood transfusions during allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, these transfusions can result in an excess of iron in the body tissues, which can negatively impact the success of transplantation. This study aimed to examine the impact of pretransplantation iron overload (IO) on the outcomes of allo-HSCT in patients with SAA. It also investigated whether iron chelation (IC) therapy is necessary to enhance transplantation outcomes in SAA patients by providing guidelines for determining when excess iron should be chelated. The study consisted of 2 parts. In cohort 1, which was retrospective and conducted from April 2012 to December 2018, SAA patients receiving their first allo-HSCT were divided into 2 groups based on their pretransplantation serum ferritin (SF) level: the IO group (SF >1000 ng/mL; n = 17) and the non-IO group (SF ≤1000 ng/mL; n = 48). Cohort 2, a prospective clinical trial conducted from January 2019 to July 2020, included SAA patients diagnosed with IO who were treated with IC therapy using deferasirox at a dose of 10 to 30 mg/kg. Patients were separated into 2 groups based on their pretransplantation SF level: the IC success (ICsuccess) group (SF ≤1000 ng/mL; n = 18) and the IC failure (ICfailure) group (SF >1000 ng/mL; n = 28). All participants were evaluated for the correlation between pretransplantation SF level and transplantation outcomes. A P value <.05 was considered statistically significant. There was no significant difference in the speed of engraftment among the 3 cell lineages or in the incidence of 100-day grade II-IV acute graft-versus-host disease (aGVHD), grade III-IV aGVHD, or 3-year chronic GVHD between the 2 groups in both cohorts. Of note, however, in cohort 1, both 1-year overall survival (OS) (41.2% versus 83.3%; P < .001) and 3-year OS (35.3% versus 83.3%; P < .001) were significantly worse in the IO group. Furthermore, 180-day transplantation related mortality (TRM) (47.1% versus 14.6%; P = .005) and 1-year TRM (52.9% versus 16.7%; P = .002) were significantly higher in the IO group. The IO group was significantly associated with inferior 3-year OS in both univariate and multivariate analyses. In cohort 2, 1-year OS (88.9% versus 42.9%; P = .003) and 3-year OS (83.3% versus 42.9%; P = .007) were significantly better in the ICsuccess group, whereas 180-day TRM (11.1% versus 39.3%; P = .040) and 1-year TRM (11.1% versus 57.1%; P = .003) were significantly lower in the ICsuccess group. These differences were confirmed in both univariate and multivariate analyses. This study involving 2 cohorts shows that pre-HSCT IO has a negative impact on transplantation outcomes in SAA patients. Chelating excess iron with an SF level <1000 ng/mL was found to be necessary and could potentially improve the outcomes.

Evolution of Iron Burden in Acquired Aplastic Anemia: a Cohort Study of More Than 3-Year Follow-Up

Iron Metabolism Before Allo-Hsct in Patients with Acute Leukemia and Impact of Iron Overload on Transplantation

The Clinical Significance of Iron Overload and Iron Metabolism in Myelodysplastic Syndrome and Acute Myeloid Leukemia

A Multivariate Analysis of the Risk of Iron Deficiency in Plateletpheresis Donors Based on Logistic Regression

Current Treatment Patterns of Aplastic Anemia in China: A Prospective Cohort Registry Study

Impact of Iron Overload and Iron Removal Therapy on Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in the Patients with Severe Aplastic Anemia

Impact of Iron Overload and Iron Chelation with Deferasirox on Outcomes of Patients with Severe Aplastic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation.

Impact of iron overload on poor graft function after allo-HSCT in a patient with transfusion-dependent low-risk MDS: A case report and literature review

Clinical outcomes of transfusion-associated iron overload in patients with refractory chronic anemia.

Study of Abnormal Iron Metabolism Parameters and Iron Overload in Patients with Myelodysplastic Syndromes

Current understanding of iron overload hazard in patients with myelodysplastic syndrome]

Treatment Outcome of 301 Aplastic Anemia Patients in China: a 10-Year Follow-Up and Real-World Data from Single Institute Experience

Bone mineral density in patients with transfusion-associated iron accumulation

[Clinical Study of Iron Metabolism Indicators in Ineffective Hematopoiesis of Myelodysplastic Syndrome].

Transfusion-dependent non-severe aplastic anemia: characteristics and outcomes in the clinic

Maternal and Fetal Outcomes and Related Risk Factors of 85 Cases with Aplastic Anemia in Pregnancy:A Retrospective Case Control Study

Long-term follow-up of clonal evolutions in 802 aplastic anemia patients: a single-center experience

The contribution of iron deficiency to the risk of peripartum transfusion: a retrospective case control study

Durable Red Blood Cell Transfusion Independence in a Patient with an MDS/MPN Overlap Syndrome Following Discontinuation of Iron Chelation Therapy

Association of Abnormal Iron Status with the Occurrence and Prognosis of Peritoneal Dialysis-Related Peritonitis: A Longitudinal Data-Based 10-Year Retrospective Study

Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy